All In MedTech

Device Trial Radar · NCT02577302

CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology

Multi-center, Prospective, Randomized, Controlled, Non-Inferiority, Clinical Trial of Chronic Afferent Nerve Stimulation (CAN-Stim) of the Tibial Nerve Versus Sacral Nerve Stimulation (SNS) in the Treatment of Urinary Urgency Incontinence Resulting From Refractory Overactive Bladder (OAB)

Last checked: Nov 19, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 21, 2018

Primary completion

Oct 2025

Study completion Oct 2025

Sponsor

Lead sponsor
Uro Medical CorporationNot on our public-company list
Sponsor type
Industry
First posted
Oct 16, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.

Conditions

  • Urinary Incontinence, Urge

Interventions

  • CAN-Stim - Protect CAN-Stim SystemDevice

    CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.

  • SNS - InterStim® SystemDevice

    Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators ("bellows" response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate: a ≥ 50% reduction in number of urgency related incontinence episodesTime frame: 3 Months
  2. device- and procedure-related Adverse Events (AE)Time frame: 3 Months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Tilda Research Inc

    Laguna Hills, California · Recruiting

  • Kaiser Permanente

    Los Angeles, California · Recruiting

  • University of California Irvine Medical Center

    Orange, California · Recruiting

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.